Navigation Links
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
2. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
3. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
4. Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
5. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
8. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
9. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
10. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
11. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015  Array ... financial results for the fourth quarter and ... a conference call to discuss those results ... Chief Executive Officer will lead the call. ... Eastern TimeToll-Free:(844) 464-3927Toll:(765) 507-2598Pass Code: 68380312 Webcast, ...
(Date:7/27/2015)... 2015  Linear accelerators used to treat patients ... only adequate space for the equipment itself, but ... to the size and complexity of the technology, ... addition of a new vault constitutes a formidable ... of patient treatment: with potential negative long-term effects ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: ... its Solaris therapeutic modality products. This approval allows the company to ... other countries around the world. "Receiving the CE Mark ... efforts," stated Kelvyn H. Cullimore Jr. , president and CEO ... distribution network into China , Japan ...
Breaking Medicine Technology:Accelerating the Design Process for Cancer Treatment Centers 2Accelerating the Design Process for Cancer Treatment Centers 3Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... March 22, 2011 Instrumentation Laboratory (IL) today announced ... ($644.9 million US). This represents 11.5% growth v. previous ... the Company,s two major business segments, Critical Care and ... (11.9% in local currencies) and 9.7% (8.9% in local ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... currently Valeant,s Chief Executive Officer (CEO), as Chairman of the ... the Valeant Board as an independent Board Director and Lead ... and has agreed to extend his contract through to February ...
Cached Medicine Technology:Instrumentation Laboratory Achieves Record Sales in 2010 2Instrumentation Laboratory Achieves Record Sales in 2010 3
(Date:7/27/2015)... ... July 27, 2015 , ... A Harris County jury awarded a ... against Canadian stock promoter Robert Kubbernus based on findings of fraud and violations of ... accepted by the court in Cause No. 2010-09675; Jo Ann Schermerhorn, et al v. ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Throughout its 20 ... premier doctors and medical providers working on a lien basis. As the personal ... wide range of providers from chiropractors, to orthopedists, to pain management physicians, to psychologists ...
(Date:7/27/2015)... , ... July 27, 2015 , ... According to an ... rate of hepatitis C has increased in Tennessee stemming from intravenous drug use. Intravenous ... medical professionals at risk for contracting communicable diseases including Hepatitis B and C and ...
(Date:7/27/2015)... ... ... SupplyLogic, a marketing execution partner based in metro New York and Chicago has ... Founder and CEO Kevin Sherlock discusses the value in supply chain visibility by quoting ... it the closer you get to the ocean, the more seafood costs?’ Those of ...
(Date:7/27/2015)... ... July 27, 2015 , ... Continuing their ongoing ... serving the greater San Antonio area, is launching a joint charity effort with ... Big Brother Big Sister Organization of South Texas is committed to serving underprivileged ...
Breaking Medicine News(10 mins):Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3Health News:SupplyLogic Releases First Executive Blog on Supply Chain Management Issues 2Health News:Shacklett Insurance Team Joins Local Chapter of Big Brother Big Sister Organization to Initiate Joint Charity Effort to Benefit Children in San Antonio 2Health News:Shacklett Insurance Team Joins Local Chapter of Big Brother Big Sister Organization to Initiate Joint Charity Effort to Benefit Children in San Antonio 3
... Health ChoicesMIDLAND, Mich., Feb. 11 With Earth ... to go green. By implementing Health Enhancement ... www.HealthEnhancementSystems.com ), Green Planet Wellness ... ), participants learn small steps that can add ...
... Feb. 11 Doctors with Plastic Surgery Services ... in the area to offer LATISSE(TM), the new ... growing them darker, fuller and longer. LATISSE,s ... such as BOTOX(R) and Juvederm(TM). The active ingredient ...
... VIEJO, Calif., Feb. 11 Valeant Pharmaceuticals International (NYSE: ... host a conference call on Tuesday, February 24, 2009 ... results for the 2008 fourth quarter and year.The dial-in ... confirmation code 83660030. International callers should ...
... to start of chronic lymphocytic leukemia , , WEDNESDAY, ... appear in the blood years before a person is ... , They added that this finding may help improve ... stages of leukemia, and how the disease progresses. , ...
... with atrial fibrillation , , WEDNESDAY, Feb. 11 (HealthDay News) ... produced promising results in its latest trial. , The ... affects an estimated 2.2 million Americans. The upper chambers ... the formation of blood clots that can block a ...
... 11 Symmetry Medical Inc. (NYSE: SMA ), ... device industry and other medical markets, announced today that it ... for the period ending January 3, 2009 before the market ... an accompanying conference call at 9:00 a.m. ET on Tuesday, ...
Cached Medicine News:Health News:Green Planet Wellness Helps Employers Have Big Environmental Impact 2Health News:Long and Lovely Lashes by LATISSE(TM) Now Available Through Plastic Surgery Services of Fredericksburg 2Health News:Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009 2Health News:Signs of Leukemia Show Up Years Before Diagnosis 2Health News:New Drug Shows Promise Against Heartbeat Abnormality 2Health News:New Drug Shows Promise Against Heartbeat Abnormality 3Health News:Symmetry Medical to Report Fourth Quarter and Full Year 2008 Financial Results on February 24, 2009 2
... Endoscopic CycloPhotocoagulation (ECP) is a surgical approach ... and visualized laser application. The ciliary body ... the surgeon, from the anterior or posterior ... The target tissues are easily and accurately ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
Medicine Products: